Status:
COMPLETED
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
Lead Sponsor:
LEO Pharma
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism. This study also ...
Eligibility Criteria
Inclusion
- Subjects must provide informed consent
- Men or women aged 18 years or more
- Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low Molecular Weight Heparin before entry into the study
Exclusion
- \- Contraindication to the use of Low Molecular Weight Heparin
Key Trial Info
Start Date :
November 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
419 Patients enrolled
Trial Details
Trial ID
NCT01803022
Start Date
November 1 2012
End Date
July 1 2013
Last Update
February 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Saint Louis
Paris, France, 75010